Trial intelligence / Profile preview

Bioequivalence study of linagliptin 5 mg tablets versus Trajenta 5 mg tablets in healthy Thai volunteers under fasting conditions

TCTR20210706001Phase 1Not yet recruiting

Sponsor
Bio-innova
Start
Nov 2021
Modality
Small Molecules
Countries
1
01

Overview

Phase 1, randomised, open-label trial of linagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Bio-innova. Planned start Nov 2021; status: not yet recruiting.

02

Drugs

linagliptin
03

Conditions

type 2 diabetes mellitus (T2DM)

Beyond the preview

Go deeper on TCTR20210706001.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on TCTR20210706001.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call